Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae189 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Lorin Begré und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, Hepatitis B Surface Antigens, RNA, Viral. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, NEAT-ID Foundation, Department of Teaching and Research, Inselspital, Bern University Hospital.
Abstract (Originalsprache)
Background
We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study.
Methods
We included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates.
Results
HBsAg loss occurred after a median of 4 years (IQR, 1–8). All participants with HBsAg loss achieved suppressed HBV DNA and undetectable HBV RNA preceding undetectable quantitative HBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After 2 years of tenofovir therapy, an HBV RNA decline ≥1 log10 copies/mL had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/mL had 91.0% sensitivity and 64.5% specificity.
Conclusions
HBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in persons with HIV. HBcrAg remained detectable in approximately 20% of persons with HBsAg loss and 50% of persons without HBsAg loss.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland.
- Graduate School for Health Sciences, University of Bern, Switzerland.
- Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, The Netherlands.
- Stichting hiv monitoring Amsterdam, The Netherlands.
- Department of Infectious Diseases, Amsterdam UMC location University of Amsterdam, The Netherlands.
- Department of Infectious Diseases, Amsterdam Institute for Infection and Immunity, The Netherlands.
ORCID-Profile: Lorin Begré, Anders Boyd, Marie-Laure Plissonnier, Barbara Testoni, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Caroline Scholtès, Charles Béguelin, Jürgen K Rockstroh, Huldrych F Günthard, Alexandra Calmy, Matthias Cavassini, Hans H Hirsch, Patrick Schmid, Enos Bernasconi, Massimo Levrero, Gilles Wandeler, Fabien Zoulim, Andri Rauch
Förderung
- Gilead Sciences
- NEAT-ID Foundation
- Department of Teaching and Research, Inselspital, Bern University Hospital
- Liquid Biobank Inselspital Bern
- Swiss National Science Foundation
- SHCS research foundation
- Young Talents in Clinical Research
- program
Zitieren
APA
Begré, L., Boyd, A., Plissonnier, M. L., Testoni, B., Salazar-Vizcaya, L., Suter-Riniker, F., Scholtès, C., Béguelin, C., Rockstroh, J. K., Günthard, H. F., Calmy, A., Cavassini, M., Hirsch, H. H., Schmid, P., Bernasconi, E., Levrero, M., Wandeler, G., Zoulim, F., Rauch, A., & Swiss HIV Cohort Study (2024). Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae189
Vancouver
Begré L, Boyd A, Plissonnier ML, Testoni B, Salazar-Vizcaya L, Suter-Riniker F, et al. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae189
BibTeX
@article{Begr2024,
author = {Begré, Lorin and Boyd, Anders and Plissonnier, Marie-Laure and Testoni, Barbara and Salazar-Vizcaya, Luisa and Suter-Riniker, Franziska and Scholtès, Caroline and Béguelin, Charles and Rockstroh, Jürgen K and Günthard, Huldrych F and Calmy, Alexandra and Cavassini, Matthias and Hirsch, Hans H and Schmid, Patrick and Bernasconi, Enos and Levrero, Massimo and Wandeler, Gilles and Zoulim, Fabien and Rauch, Andri and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
title = {Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae189}
}
EUVIMED